Abstract
Studies have shown that TNFR1 is a key factor in the tumor microenvironment that is dependent on the TNF-α-initiated cascade for tumorigenesis. In this present study, we found that TNFR1 is over-expressed in ovarian cancer, which is relevant to both clinical survival and disease free status. Knockdown of TNFR1 dramatically attenuates malignant phenotypes, including proliferation and colony growth in soft agar, as well as glycolysis in ovarian cancer cells. Unexpectedly, knocking down TNFR1 blocks EGF-induced p-AKT and p-p70S6K expression and EGF-induced cell transformation through PIK3-p110beta rather than p110alpha expression. Taken together, our data provide evidence that TNFR1 plays a critical role in ovarian cancer and show that the EGF induced signaling pathway is independent of the TNF-α triggering cascade signal. Therefore, TNFR1 may serve as a prognostic molecule in ovarian cancer.
Keywords: EGF pathway, independent on TNF-α, Ovarian cancer, PIK3-P110beta, TNFR1, tumorigenicity.
Current Molecular Medicine
Title:TNFR1 Regulates Ovarian Cancer Cell Tumorigenicity Through PIK3CB-p110Beta
Volume: 15 Issue: 5
Author(s): C. Peng, J. Su, W. Zeng, X. Zhang and X. Chen
Affiliation:
Keywords: EGF pathway, independent on TNF-α, Ovarian cancer, PIK3-P110beta, TNFR1, tumorigenicity.
Abstract: Studies have shown that TNFR1 is a key factor in the tumor microenvironment that is dependent on the TNF-α-initiated cascade for tumorigenesis. In this present study, we found that TNFR1 is over-expressed in ovarian cancer, which is relevant to both clinical survival and disease free status. Knockdown of TNFR1 dramatically attenuates malignant phenotypes, including proliferation and colony growth in soft agar, as well as glycolysis in ovarian cancer cells. Unexpectedly, knocking down TNFR1 blocks EGF-induced p-AKT and p-p70S6K expression and EGF-induced cell transformation through PIK3-p110beta rather than p110alpha expression. Taken together, our data provide evidence that TNFR1 plays a critical role in ovarian cancer and show that the EGF induced signaling pathway is independent of the TNF-α triggering cascade signal. Therefore, TNFR1 may serve as a prognostic molecule in ovarian cancer.
Export Options
About this article
Cite this article as:
Peng C., Su J., Zeng W., Zhang X. and Chen X., TNFR1 Regulates Ovarian Cancer Cell Tumorigenicity Through PIK3CB-p110Beta, Current Molecular Medicine 2015; 15 (5) . https://dx.doi.org/10.2174/1566524015666150630125734
DOI https://dx.doi.org/10.2174/1566524015666150630125734 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Non-Lipid Effects of Statins: Emerging New Indications
Current Vascular Pharmacology Glycosides from Medicinal Plants as Potential Anticancer Agents: Emerging Trends Towards Future Drugs
Current Medicinal Chemistry Cancer Resistance to Type II Topoisomerase Inhibitors
Current Medicinal Chemistry Aerosol Delivery in the Treatment of Lung Cancer
Current Cancer Drug Targets Recent Patents, Formulation and Characterization of Nanoliposomes
Recent Patents on Drug Delivery & Formulation Molecular Predictors of Efficacy to Anti-EGFR Agents in Colorectal Cancer Patients
Current Cancer Drug Targets Advances in Hydrogels Applied to Degenerative Diseases
Current Pharmaceutical Design Biomarkers of Angiogenesis and their Role in Patient Selection for Antiangiogenic Therapy
Current Angiogenesis (Discontinued) Validation and Development of N-glycan as Biomarker in Cancer Diagnosis
Current Pharmacogenomics and Personalized Medicine A Review on the Use of Statins and Tocotrienols, Individually or in Combination for the Treatment of Osteoporosis
Current Drug Targets Streamlined In Vivo Selection and Screening of Human Prostate Carcinoma Avid Phage Particles for Development of Peptide Based In Vivo Tumor Imaging Agents
Combinatorial Chemistry & High Throughput Screening Inhibiting Breast Cancer Progression by Exploiting TGFβ Signaling
Current Drug Targets Pharmacogenomics of Xenobiotic Metabolizing Enzymes in South American Populations
Current Pharmacogenomics Atomic Layers in Electrochemical Biosensing Applications - Graphene and Beyond
Current Organic Chemistry Role of Natural Phenolic Compounds in Cancer Chemoprevention via Regulation of the Cell Cycle
Current Pharmaceutical Biotechnology Therapeutic Potential of Drug Delivery by Means of Lipid Nanoparticles: Reality or İllusion?
Current Pharmaceutical Design The Chemokine Receptor CXCR4 as a Therapeutic Target for Several Diseases
Mini-Reviews in Medicinal Chemistry Melatonin Could Be Beneficial in SARS-CoV-2 Therapy
The Natural Products Journal Mitogen-activated Protein Kinase (MAPK) Interacting Kinases 1 and 2 (MNK1 and MNK2) as Targets for Cancer Therapy: Recent Progress in the Development of MNK Inhibitors
Current Medicinal Chemistry The Development of Oncolytic Adenovirus Therapy in the Past and Future - For the Case of Pancreatic Cancer
Current Cancer Drug Targets